Floatz logo

Therapeutic Asset Ratings

615 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Cetuximab
FAPI PET
Fudan UniversityP2CCC (53)
Cetuximab
Peritoneal (Metastatic) Cancer
Fudan UniversityP2CCC (53)
Cetuximab
RAS Wild Type mCRC
Fudan UniversityP2CCC (53)
CIS-DIAMMINEDICHLOROPLATINUM II
HR+HER2- Breast Cancer
Fudan UniversityP2CCC (53)
CIS-DIAMMINEDICHLOROPLATINUM II
Paget Disease, Extramammary
Fudan UniversityP2CCC (53)
CIS-DIAMMINEDICHLOROPLATINUM II
Perioperative Immunotherapy
Fudan UniversityP2CCC (53)
CIS-DIAMMINEDICHLOROPLATINUM II
Urachal Cancer
Fudan UniversityP2CCC (53)
Cromoglicic acid
Triple-Negative Breast Carcinoma
Fudan UniversityP2CCC (53)
Cyclophosphamide
Hormone Receptor Negative Tumor
Fudan UniversityP2CCC (53)
Cyclophosphamide
Maintenance Therapy
Fudan UniversityP2CCC (53)
DALPICICLIB ISETIONATE
Hormone Receptor Negative Tumor
Fudan UniversityP2CCC (53)
DALPICICLIB ISETIONATE
Hormone Receptor Positive Tumor
Fudan UniversityP2CCC (53)
Datopotamab Deruxtecan
Metastatic Breast Cancer ( HER2 Negative)
Fudan UniversityP2CCC (53)
Duloxetine
Solid Tumour
Fudan UniversityP2CCC (53)
Efavirenz
Triple-Negative Breast Carcinoma
Fudan UniversityP2CCC (53)
Eloxatin
ctDNA
Fudan UniversityP2CCC (53)
Eloxatin
Moderately Hypofractionated Radiotherapy
Fudan UniversityP2CCC (53)
Eloxatin
pMMR/MSS
Fudan UniversityP2CCC (53)
Eloxatin
Serplulimab
Fudan UniversityP2CCC (53)
Endostar
Acral Lentiginous Melanoma
Fudan UniversityP2CCC (53)
Endostar
Advanced Mucosal Melanoma
Fudan UniversityP2CCC (53)
Endostar
Cutaneous Melanoma
Fudan UniversityP2CCC (53)
Entrectinib
ROS1 Fusion Positive
Fudan UniversityP2CCC (53)
Envafolimab
Mucosal Melanoma
Fudan UniversityP2CCC (53)
Envafolimab
Nonpapillary Renal Cell Carcinoma
Fudan UniversityP2CCC (53)
Showing 226 to 250 of 615 assets
PreviousPage 10 of 25Next